|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TUBGCP5 |
Gene summary for TUBGCP5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TUBGCP5 | Gene ID | 114791 |
| Gene name | tubulin gamma complex associated protein 5 | |
| Gene Alias | GCP5 | |
| Cytomap | 15q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q96RT8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114791 | TUBGCP5 | HCC1_Meng | Human | Liver | HCC | 8.55e-19 | 1.74e-02 | 0.0246 |
| 114791 | TUBGCP5 | HCC1 | Human | Liver | HCC | 6.74e-06 | 4.08e+00 | 0.5336 |
| 114791 | TUBGCP5 | HCC2 | Human | Liver | HCC | 3.24e-02 | 3.02e+00 | 0.5341 |
| 114791 | TUBGCP5 | S028 | Human | Liver | HCC | 3.90e-07 | 3.55e-01 | 0.2503 |
| 114791 | TUBGCP5 | S029 | Human | Liver | HCC | 4.82e-02 | 2.58e-01 | 0.2581 |
| 114791 | TUBGCP5 | C21 | Human | Oral cavity | OSCC | 9.90e-09 | 3.33e-01 | 0.2678 |
| 114791 | TUBGCP5 | C30 | Human | Oral cavity | OSCC | 6.73e-07 | 3.14e-01 | 0.3055 |
| 114791 | TUBGCP5 | C38 | Human | Oral cavity | OSCC | 2.85e-05 | 5.62e-01 | 0.172 |
| 114791 | TUBGCP5 | C08 | Human | Oral cavity | OSCC | 5.82e-04 | 1.36e-01 | 0.1919 |
| 114791 | TUBGCP5 | LN22 | Human | Oral cavity | OSCC | 1.32e-04 | 5.05e-01 | 0.1733 |
| 114791 | TUBGCP5 | SYSMH2 | Human | Oral cavity | OSCC | 2.23e-09 | 2.15e-01 | 0.2326 |
| 114791 | TUBGCP5 | SYSMH3 | Human | Oral cavity | OSCC | 1.11e-06 | 2.28e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005125822 | Liver | HCC | protein polymerization | 182/7958 | 297/18723 | 4.17e-11 | 1.58e-09 | 182 |
| GO:000705111 | Liver | HCC | spindle organization | 116/7958 | 184/18723 | 1.40e-08 | 3.40e-07 | 116 |
| GO:005122511 | Liver | HCC | spindle assembly | 75/7958 | 117/18723 | 1.92e-06 | 2.67e-05 | 75 |
| GO:0046785 | Liver | HCC | microtubule polymerization | 51/7958 | 83/18723 | 3.82e-04 | 2.61e-03 | 51 |
| GO:0007020 | Liver | HCC | microtubule nucleation | 25/7958 | 35/18723 | 5.05e-04 | 3.29e-03 | 25 |
| GO:00311222 | Liver | HCC | cytoplasmic microtubule organization | 35/7958 | 56/18723 | 2.00e-03 | 1.01e-02 | 35 |
| GO:0031109 | Liver | HCC | microtubule polymerization or depolymerization | 68/7958 | 122/18723 | 2.14e-03 | 1.08e-02 | 68 |
| GO:00070517 | Oral cavity | OSCC | spindle organization | 117/7305 | 184/18723 | 1.16e-11 | 4.17e-10 | 117 |
| GO:005125820 | Oral cavity | OSCC | protein polymerization | 169/7305 | 297/18723 | 2.57e-10 | 7.17e-09 | 169 |
| GO:00512255 | Oral cavity | OSCC | spindle assembly | 73/7305 | 117/18723 | 2.51e-07 | 3.96e-06 | 73 |
| GO:00070204 | Oral cavity | OSCC | microtubule nucleation | 28/7305 | 35/18723 | 8.71e-07 | 1.19e-05 | 28 |
| GO:00311226 | Oral cavity | OSCC | cytoplasmic microtubule organization | 39/7305 | 56/18723 | 3.29e-06 | 3.93e-05 | 39 |
| GO:00467855 | Oral cavity | OSCC | microtubule polymerization | 53/7305 | 83/18723 | 3.96e-06 | 4.65e-05 | 53 |
| GO:00311093 | Oral cavity | OSCC | microtubule polymerization or depolymerization | 68/7305 | 122/18723 | 1.29e-04 | 9.21e-04 | 68 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TUBGCP5 | SNV | Missense_Mutation | novel | c.208N>A | p.Glu70Lys | p.E70K | Q96RT8 | protein_coding | deleterious(0.01) | benign(0.057) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TUBGCP5 | SNV | Missense_Mutation | novel | c.2350G>A | p.Val784Ile | p.V784I | Q96RT8 | protein_coding | tolerated(0.44) | benign(0.001) | TCGA-AR-A1AU-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| TUBGCP5 | SNV | Missense_Mutation | novel | c.787N>T | p.Val263Phe | p.V263F | Q96RT8 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-C8-A26V-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | CR |
| TUBGCP5 | insertion | Frame_Shift_Ins | novel | c.2166_2167insGTCTCTACTAAAAATACAAAAAGCATGGTGGC | p.Met723ValfsTer12 | p.M723Vfs*12 | Q96RT8 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| TUBGCP5 | insertion | In_Frame_Ins | novel | c.1169_1170insGGCAAGTTCTATTTCATTTTT | p.Asp390delinsGluAlaSerSerIleSerPhePhe | p.D390delinsEASSISFF | Q96RT8 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TUBGCP5 | insertion | Frame_Shift_Ins | novel | c.2881_2882insG | p.Ala961GlyfsTer26 | p.A961Gfs*26 | Q96RT8 | protein_coding | TCGA-C8-A26X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| TUBGCP5 | deletion | Frame_Shift_Del | novel | c.2622delN | p.Glu874AspfsTer3 | p.E874Dfs*3 | Q96RT8 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| TUBGCP5 | SNV | Missense_Mutation | novel | c.1744N>A | p.Ala582Thr | p.A582T | Q96RT8 | protein_coding | tolerated(0.65) | benign(0.161) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TUBGCP5 | SNV | Missense_Mutation | rs750751827 | c.28N>T | p.Arg10Trp | p.R10W | Q96RT8 | protein_coding | tolerated_low_confidence(0.14) | benign(0.39) | TCGA-DS-A0VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TUBGCP5 | SNV | Missense_Mutation | novel | c.2564N>G | p.Leu855Arg | p.L855R | Q96RT8 | protein_coding | tolerated(0.41) | benign(0) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |